%0 Journal Article
%T DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes
%A Angelo Avogaro
%A Benedetta Maria Bonora
%A Gian Paolo Fadini
%A Mario Plebani
%A Martina Zaninotto
%A Mattia Albiero
%J Archive of "Cardiovascular Diabetology".
%D 2017
%R 10.1186/s12933-017-0507-9
%X Use of dipeptidyl peptidase-4 inhibitors (DPP4-i) for the treatment of type 2 diabetes (T2D) has been associated with a possible increase in the risk for heart failure (HF). B-type natriuretic peptide (BNP), which is both a biomarker of HF and a hemodynamically active hormone, is a substrate of DPP-4. We herein tested the acute effects of the DPP-4i linagliptin on BNP and NT-proBNP in a cross-over placebo-controlled trial in patients with T2D with and without chronic kidney disease (CKD)
%K Heart failure
%K Enzyme
%K Proteases
%K Linagliptin
%K Kidney disease
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301429/